News
Ekterly becomes the first FDA-approved oral on-demand treatment for hereditary angioedema in patients aged 12 years and older ...
16h
Barchart on MSNThe Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.Moderna (MRNA), an undervalued name in the biotech space, rose to prominence during the COVID-19 pandemic. This occurred when ...
The Food and Drug Administration (FDA) has approved Ekterly ® (sebetralstat) for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older.
Ekterly is the first and only oral on-demand therapy for treating attacks associated with hereditary angioedema – – DRI Healthcare is entitled to a ...
Health groups led by the American Academy of Pediatrics filed a lawsuit against HHS Secretary Robert F. Kennedy Jr. on Monday ...
17h
Capital Market on MSNNifty ends above 25,500 level; consumer durables shares tumbleThe domestic equity benchmarks ended with modest gains today, buoyed by positive sentiment after U.S. President Donald Trump postponed the implementation of new tariffs to August 1. The Nifty settled ...
S&P Global Ratings is considering whether to reclassify Centene Corp.'s credit ratings to junk, which would strongly impact its borrowing power. Centene, the top seller of ACA health plans, is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results